SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE:
NVTA), a leading medical genetics company, today announced three
studies demonstrating the benefits of genetic testing for all
breast cancer patients, impacting treatment decisions and cancer
screening for patients and their families. The studies, which will
be presented at the 2020 San Antonio Breast Cancer Symposium
(SABCS), add to the evidence supporting universal access to genetic
information for all breast cancer patients.
![Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation) Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)](https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg)
"It's clear that current guidelines are too restrictive and, as
a result, many patients with breast cancer whose care could be
improved by access to precision medicine approaches are being
missed. Universal testing for all patients with solid tumor cancer,
including breast cancer, can help inform treatment and improve
outcomes for patients," said Robert
Nussbaum, M.D., chief medical officer of Invitae. "These
data, taken together with many other studies that demonstrate the
utility of universal testing for cancer patients, show the time has
come to expand testing guidelines to ensure all breast cancer
patients and their families can benefit from incorporating genetic
information into their care."
In a prospective, multi-center study of breast cancer patients,
one in eight patients had inherited genetic variants that could
increase their risk of more aggressive disease and inform treatment
choices. Despite the patients having inherited genetic variants,
testing rates among patients' families remained low, even when cost
was not a barrier. These findings in breast cancer patients were
part of a landmark study across various solid tumor cancers
recently published in JAMA Oncology.
Findings of a second study at the meeting underscore the impact
germline testing can have on patient outcomes. In the longitudinal
study, researchers evaluated the clinical outcomes of breast cancer
patients who had undergone testing as part of a registry that
included patients who met testing criteria and those who did not.
Notably, 60% of patients who received targeted chemotherapy based
on germline variants were in the group that did not meet testing
criteria, highlighting the possibility that certain beneficial
treatments and management changes could be inappropriately withheld
from patients if restrictive criteria persist.
The third study at the meeting examined select international
germline genetic testing criteria from Canada, Australia and the United Kingdom, and its impact on limiting
access to testing in patients and their families who may benefit
from this information. The study applied the international testing
criteria to a cohort of previously tested U.S. breast cancer
patients and found that more than 70% of patients with pathogenic
variants would have been excluded using current guidelines to
allocate germline testing. Furthermore, >80% of the pathogenic
variants detected in these out-of-criteria patients were in genes
with published management guidelines. This study demonstrates that
current international guidelines for genetic testing are overly
restrictive and miss actionable findings that could benefit breast
cancer patients and their families.
Invitae presentations at 2020 SABCS:
Poster Session 8: Wednesday, December
9 at 8:00 a.m. CT
- Pathogenic variants in hereditary cancer syndrome genes are
prevalent among breast cancer patients not meeting various ex-U.S.
genetic testing guidelines. Presented by Sarah Nielsen, MS, LCGC
- Longitudinal clinical outcomes of a multi-center universal
genetic testing registry. Presented by Peter Beitsch, MD
Spotlight Poster Discussion 10: Friday,
December 11, 2020 at 1:00 p.m.
CT
- Universal genetic testing in breast cancer patients: A
multi-center, prospective study. Presented by Brenda Ernst, MD
About Invitae
Invitae Corporation (NYSE: NVTA) is
a leading medical genetics company, whose mission is to bring
comprehensive genetic information into mainstream medicine to
improve healthcare for billions of people. Invitae's goal is to
aggregate the world's genetic tests into a single service with
higher quality, faster turnaround time, and lower prices. For more
information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the implications of the studies to be presented at the
symposium; the utility of universal access to genetic testing; the
impact of germline testing on patient outcomes; the importance of
expanding genetic testing guidelines; and the benefits of genetic
testing and information. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the company's history of losses;
the company's ability to compete; the company's failure to manage
growth effectively; the company's need to scale its infrastructure
in advance of demand for its tests and to increase demand for its
tests; the company's ability to use rapidly changing genetic data
to interpret test results accurately and consistently; security
breaches, loss of data and other disruptions; laws and regulations
applicable to the company's business; and the other risks set forth
in the company's filings with the Securities and Exchange
Commission, including the risks set forth in the company's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. These forward-looking
statements speak only as of the date hereof, and Invitae
Corporation disclaims any obligation to update these
forward-looking statements.
Contact:
Laura D'Angelo
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invitae-to-present-new-data-supporting-genetic-testing-for-all-breast-cancer-patients-at-the-2020-san-antonio-breast-cancer-symposium-301189224.html
SOURCE Invitae Corporation